.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AD03_Voclosporin.Voclosporin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AD03_Voclosporin.Voclosporin| name: | Voclosporin | |
| ATC code: | L04AD03 | route: | oral |
| compartments: | 2 | |
| dosage: | 23.7 | mg |
| volume of distribution: | 163 | L |
| clearance: | 9.1 | L/hr |
| other parameters in model implementation | ||
Voclosporin is a novel calcineurin inhibitor immunosuppressant, structurally derived from cyclosporine, and is primarily used for the treatment of lupus nephritis in adult patients. It is approved for use in multiple countries including the US (FDA, 2021).
Healthy adult volunteers (mixed sex); oral administration under fasting or fed conditions.
Mayo, PR, et al., & Foster, RT (2014). Population PKPD of voclosporin in renal allograft patients. Journal of clinical pharmacology 54(5) 537–545. DOI:10.1002/jcph.237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24243422